Thrombosis
Return to Library
Researchers at Harvard University publish new data on antithrombotics
2009 AUG 3 - (NewsRx.com) -- "Fondaparinux is an antithrombotic agent with unique properties that may offer benefit to patients beyond the current approved indications. To explore the off-label use versus approved use of fondaparinux, we initiated a single-center registry of fondaparinux use," scientists in the United States report. "During the 25-month study period, 219 patients were prescribed fondaparinux: 157 (71.7%) for prophylaxis and 62 (28.3%) patients for the treatment of thrombosis. When fondaparinux was used for prophylaxis in our registry, 94% of patients had documentation of heparin-induced thrombocytopenia (HIT)," wrote S. Baroletti and colleagues, Harvard University. The researchers concluded: "Fondaparinux warrants further evaluation in patients with HIT or suspected HIT In the meantime, its off-label use may exceed its use for FDA-approved indications.." Baroletti and colleagues published their study in Thrombosis and Haemostasis (Prescription of fondaparinux in hospitalised patients. Thrombosis and Haemostasis, 2009;101(6):1091-1094). For additional information, contact S. Baroletti, Harvard University, Brigham & Women's Hospital, Dept. of Pharmacy, School Medical, 75 Francis St., Boston, MA 02115, USA. The publisher's contact information for the journal Thrombosis and Haemostasis is: Schattauer GmbH-Verlag Medizin Naturwissenschaften, Holderlinstrasse 3, D-70174 Stuttgart, Germany. Keywords: United States, Boston, Antithrombotics, Angiology, Antithrombotic, Haemostasis, Hematology, Heparin, Thrombocytopenia, Thrombosis, Harvard University. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
